A5005611060- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Renal cell carcinoma treatment
- Multiple and Secondary Primary Cancers
- Lung Cancer Treatments and Mutations
- Uterine Myomas and Treatments
- Sarcoma Diagnosis and Treatment
- Pediatric health and respiratory diseases
- Cancer Research and Treatments
- Cancer-related cognitive impairment studies
- Gallbladder and Bile Duct Disorders
- Adrenal and Paraganglionic Tumors
- Colorectal Cancer Surgical Treatments
- Peptidase Inhibition and Analysis
- Lymphoma Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- Liver Diseases and Immunity
- Leprosy Research and Treatment
- Cancer Treatment and Pharmacology
- Salivary Gland Tumors Diagnosis and Treatment
- Ovarian cancer diagnosis and treatment
- Epigenetics and DNA Methylation
- Autoimmune and Inflammatory Disorders
Fondazione IRCCS Istituto Nazionale dei Tumori
2022-2025
Centro di Riferimento Oncologico
2024-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2024-2025
University of Udine
2025
•Validated patient-reported outcome measures were used for screening CRF and depression in advanced cancer patients.•A direct strong correlation between was found these patients, often unconsidered by clinicians.•Other different clinical risk factors the onset worsening of identified.•A comprehensive evaluation that should also consider mood disorders, could improve management. BackgroundCancer-related fatigue (CRF) is common patients with solid tumors several are described. The possible...
587 Background: Collecting Duct Carcinoma (CDC) represents 1% of all renal cell carcinomas (RCC) and is characterized by aggressive clinical behavior a particularly dismal prognosis. Cabozantinib platinum-based chemotherapy are active therapeutic options, but survival remains poor with no novel agents approved for the treatment metastatic disease. Antibody-Drug Conjugate (ADC) targeting Nectin-4 TROP-2 dramatically changing landscape Urothelial (UC). Given biological similarities between CDC...
Antiangiogenic drugs such as lenvatinib have demonstrated significant benefits in patients with hepatocarcinoma (HCC), an acceptable safety profile. However, serious side effects been documented, though rare. In this report, we describe the case of a severe and unexpected toxicity encountered after about seven months treatment. The patient developed septic state, widespread cutaneous erythema extensive necrotic involvement pelvic floor, diagnosis Fournier's gangrene (FG). Emergency surgery,...
e15558 Background: The BRAF inhibitor (BRAFi) encorafenib is currently approved in combination with the anti-EGFR agent cetuximab for patients previously treated V600E mutant CRC (mCRC). Since resistance to BRAFi can be mediated by either MAPK pathway–dependent or pathway–independent mechanisms, a triplet therapy (TT) that also includes MEK inhibitors (MEKi) might offer greater benefits than doublet treatment (DT). Moreover, TT could potentially reduce some of adverse events associated...
4595 Background: In patients (pts) with MIBC, the PURE-01 study pioneered use of neoadjuvant immunotherapy by administering 3 courses pembrolizumab before radical cystectomy (RC). Multiple reports have outlined various results this trial, but assessment very long-term benefit strategy was pending and potentially noteworthy. Methods: Pts age ≥18 y, ECOG PS 0-1, histologically confirmed cT2-T4N0M0 ineligible/refusing chemotherapy (CT), scheduled for RC received 4 cycles 200 mg on D1 Q3W,...
e16262 Background: The NAPOLI-3 trial showed the superiority of NALIRIFOX regimen over combination gemcitabine and nab-Paclitaxel (GemNabP) as first-line treatment (1LTx) advanced pancreatic cancer (PDAC), thus being candidate a reference in this setting. However, comparison with FOLFIRINOX has not yet been performed. Methods: We performed pooled analysis phase III trials that defined FOLFIRINOX, GemNabP optimal 1LTx options PDAC. Individual patient outcomes were retrieved from Kaplan Meier...
Abstract Background Mesenchymal neoplasms of the uterus encompass a diverse group tumors, with varying characteristics and origins, collectively accounting for 8% uterine malignancies. The most common variants include leiomyosarcoma, low‐grade high‐grade endometrial stromal sarcoma, adenosarcoma, undifferentiated sarcoma. Clinical presentation is often nonspecific can lead to delayed diagnosis. Uterine sarcomas are generally aggressive, resulting in poorer prognosis compared carcinomas....
ABSTRACT Background The identification of actionable molecular targets pancreatic cancer (PAC) is key to improving patient outcomes. We hypothesized O6‐methylguanine‐DNA methyltransferase ( MGMT ) silencing may occur in a subset PAC tumors, with unexplored clinical and correlates. Experimental Design leveraged sequencing data from Cancer Genome Atlas (TCGA), the Clinical Proteomic Tumor Analysis Consortium 3 (CPTAC‐3), (Australian Pancreatic Initiative) PACA‐AU cohorts characterize ‐silenced...
Abstract Background NUT carcinoma (NUTc) is a rare and aggressive malignant epithelial tumor characterized by rearrangement of the gene on chromosome 15q14. Methods In this article, we present fifth case worldwide young woman affected NUTc arising from submandibular gland, presenting as rapidly evolving mass. She underwent right scialoadenectomy received initial diagnosis high‐grade mucoepidermoid carcinoma. Due to evidence local recurrence at magnetic resonance imaging 1 month later,...
BackgroundImmunotherapy (IO) single agent or combined with chemotherapy (CT-IO) is the standard treatment for advanced non–small-cell lung cancer (aNSCLC) without driver alterations. IO efficacy in patients novel alterations not well reported.Materials and MethodsData of aNSCLC treated CT-IO any line from January 2016 to September 2022 were retrospectively collected. Patients harboring (m-cohort), including MET exon 14 skipping, BRAF (V600E atypical), RET rearrangements, HER2 point...
<h3>Introduction/Background</h3> U-LMS is a rare entity, that needs to be referred highly specialized sarcoma centers. Despite large number of genomic mutations in soft-tissue sarcomas no targeted-therapy effective and systemic chemotherapy (CT) represents gold standard treatment advanced U-LMS. The antiangiogenetic agent pazopanib an oral multitargeted tirosine-kinase inhibitor; it demonstrated benefit Progression Free Survival (PFS) 3 months phase III randomized PALETTE trial....
674 Background: The first-line treatment of metastatic pancreatic cancer involves different therapeutic regimens, among them, mFOLFIRINOX and gemcitabine-nabpaclitaxel. However, it remains to be clarified which sequence might correlate with better outcomes. aim our work was evaluate leads overall survival in this setting. Methods: We retrospectively collected data from 358 patients affected by stage IV ductal adenocarcinoma 3 Italian Institutions. Patients received or gemcitabine plus...
e15592 Background: The optimal first-line treatment for RAS wild-type (wt) metastatic colorectal cancer (mCRC) remains undetermined. Recently, several studies have explored the efficacy of regimens, including triplet chemotherapy (CT) combined with an anti-EGFR antibody, in comparison to either doublet CT anti-VEGF treatment, or alone. However, none these trials yielded conclusive results. Hence, we conducted a systematic review and explorative network meta-analysis (NMA) available data....
e18017 Background: RM HNSCC patients (pts) with combined positive score (CPS) ≥1 benefit from immunotherapy (IO), either alone or chemotherapy (CIO). No survival outcome indicators are available. We aim to characterize a real world cohort of pts treated at tertiary cancer center. Methods: analyzed 37 consecutive IO CIO 2016 2022. divided in responders (R) and non (NR) if they achieved an objective response disease stability/progression as best response. For group comparisons, we considered...